Clinical trials: Cholecalciferol
Damage Muscle, Body Weight Changes
Chronic Study on Body Composition, Training, Performance, and Recovery
The chronic phase of the study will evaluate the effects of pre-exercise and post-exercise ingestion of a multi-ingredient supplement on adaptations to a 6-week exercise program consisting of both resistance training and high…
- Conditions
- Damage Muscle, Body Weight Changes, Performance Enhancing Product Use
- Trial name
- NCT04230824
- Testing
- Pre-workout plus and Protein recovery plus, 6-week resistance training program
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Postmenopausal Osteoporosis With Pathological Fracture
Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo
The primary objective of this study is to compare efficacy and safety of two formulations of teriparatide 20 mcg/day plus calcium and vitamin D in postmenopausal women with osteoporosis.
- Trial name
- NCT01945788
- Testing
- Teriparatide (rDNA origin)
- Where
- Argentina
- Volunteers
- 110 people
- Sponsor
- Bio Sidus SA
Multiple Myeloma Stage I
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma.
- Trial name
- NCT00171925
- Testing
- Zoledronic acid, Calcium / Vitamin D
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
- Trial name
- NCT00763555
- Testing
- CD 2027, Calcitriol Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Galderma R&D
Healthy
Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers
The purpose of this study is compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Bonviva (150mg Ibandronate, qd) after oral administration in healthy adult…
- Trial name
- NCT01429675
- Testing
- bonviva
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Healthy
DP-R213 Pharmacokinetics Study
A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male…
- Trial name
- NCT02762643
- Testing
- DP-R213, Raloxifene, Cholecaliferol
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Secondary Hyperparathyroidism, Renal Failure
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who…
- Conditions
- Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
- Trial name
- NCT00123461
- Testing
- Hectorol (doxercalciferol capsules), 0.5mcg
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 70 people
- Sponsor
- Genzyme, a Sanofi Company
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Obesity, Rhinitis
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application
The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized…
- Conditions
- Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds
- Trial name
- NCT02758990
- Testing
- Vitamin A, Vitamin B6, Vitamin C
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Verifomics LLC
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Trial name
- Asteroid (NCT03118570)
- Testing
- setrusumab, Calcium, Vitamin D
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 112 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Dietary Supplement
Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia
This is a mechanistic, single-center, double-blind, placebo- and active-controlled, three-time-period, crossover study to evaluate the effect of sprinkled format REDUCOSE compared to placebo (double-blind; confirmative) and…
- Trial name
- Stardust (NCT04877366)
- Testing
- Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
- Where
- 2 sites in United States, Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
Chemotherapy-Induced Alopecia
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is…
- Trial name
- NCT01588522
- Testing
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- BPGbio
Healthy
A Drug-drug Interaction Study of DP-R213
The purpose of this study is to learn about the effect of raloxifene on how the body absorbs and processes cholecalciferol and how cholecalciferol affects raloxifene when they are taken together.
- Trial name
- NCT02654093
- Testing
- Cholecalciferol, Raloxifene, Cholecalciferol and Raloxifene co-administration
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Female Infertility
Myo-inositol and Vitamin D3 During IVF
Administration of a multicomponent dietary supplement (myo-inositol, vitamin D3, folic acid and melatonin) to women undergoing IVF procedures.
- Trial name
- NCT04019899
- Testing
- control group, study group
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Lo.Li.Pharma s.r.l
Relapsing-Remitting Multiple Sclerosis
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple…
- Trial name
- SOLAR (NCT01285401)
- Testing
- VigantOL oil plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
- Where
- 38 sites in Austria, Denmark and 10 more
- Volunteers
- 260 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Trial name
- IMPACT SHPT (NCT00977080)
- Testing
- Paricalcitol, Cinacalcet
- Where
- 83 sites in United States, Czechia and 10 more
- Volunteers
- 272 people
- Sponsor
- Abbott
Elderly, Frail
Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects
The study will explore multiple mobility function tests as well as functional and neuropsychological tests in elderly subjects at risk for falls and disability, before and after 4-month exercise and/or Vitamin D intervention.
- Trial name
- NCT00249704
- Testing
- Vitamin D + Exercise
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Secondary Hyperparathyroidism
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National…
- Trial name
- NCT00135304
- Testing
- Sensipar®, Vitamin D
- Volunteers
- 170 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.